Eckert & Ziegler SE (CHIX:EUZD) Total Liabilities : €217.2 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Eckert & Ziegler SE Total Liabilities?

Eckert & Ziegler SE's Total Liabilities for the quarter that ended in Dec. 2024 was €217.2 Mil.

Eckert & Ziegler SE's quarterly Total Liabilities increased from Jun. 2024 (€222.88 Mil) to Sep. 2024 (€230.65 Mil) but then declined from Sep. 2024 (€230.65 Mil) to Dec. 2024 (€217.18 Mil).

Eckert & Ziegler SE's annual Total Liabilities increased from Dec. 2022 (€193.83 Mil) to Dec. 2023 (€215.27 Mil) and increased from Dec. 2023 (€215.27 Mil) to Dec. 2024 (€217.18 Mil).

Eckert & Ziegler SE Total Liabilities Historical Data

The historical data trend for Eckert & Ziegler SE's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eckert & Ziegler SE Total Liabilities Chart

Eckert & Ziegler SE Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

143.08

155.20

193.83

215.27

217.18

Eckert & Ziegler SE Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															215.27	219.51	222.88	230.65	217.18

Eckert & Ziegler SE Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Eckert & Ziegler SE's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	72.218	+	(46.084	+	88.704
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	10.177	+	0)
	=	217.2

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	442.396	-	225.213
	=	217.2

Eckert & Ziegler SE's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	72.218	+	(46.084	+	88.704
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	10.177	+	0)
	=	217.2

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	442.396	-	225.213
	=	217.2

Eckert & Ziegler SE Total Liabilities Related Terms

Thank you for viewing the detailed overview of Eckert & Ziegler SE's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Eckert & Ziegler SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Eckert & Ziegler SE (CHIX:EUZd) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

1EUZ:Italy 0NZY:UK EUZ:Germany EUZG:Austria

Address

Robert-Rossle-Street 10, Berlin, BB, DEU, 13125

Website

https://www.ezag.com

Eckert & Ziegler SE is a provider of isotope technology for medical, scientific, and industrial use. It is predominantly engaged in the business of cancer therapy, industrial radiometry, and nuclear medical imaging. The company's segments are Medical, Isotope Products, and Other. The Isotope Products segment which generates key revenue, manufactures and distributes standards and radiation sources for medical and industrial purposes. The Medical segment provides pharmaceutical-quality radioactive ingredients and markets products for the treatment and diagnosis of cancers. The Other segment comprises the items of the holding company. Geographically, the company generates a majority of its revenue from Europe and the rest from North America, Asia/Pacific, and other regions.

Eckert & Ziegler SE Headlines

No Headlines